Insmed to Present at the 36th Annual Cowen & Company Healthcare Conference
10 Mars 2016 - 1:46AM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today reported that company management will participate at the 36th
Annual Cowen & Company Healthcare Conference on Tuesday,
March 8, 2016 in Boston. Andy Drechsler, chief financial officer of
Insmed, will deliver a corporate overview at 8:00 AM ET.
Mr. Drechsler’s presentation will be webcast live and can be
accessed by visiting the investor relations section of the
company’s website at www.insmed.com. The webcast will be archived
for a period of 90 days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE™
(liposomal amikacin for inhalation) in nontuberculous mycobacteria
(NTM) lung disease, a rare and often chronic infection that is
capable of causing irreversible lung damage and can be fatal. There
are currently no products indicated for the treatment of NTM lung
disease in the United States or European Union (EU). In the EU, the
company has filed a marketing authorization application seeking
approval of ARIKAYCE for use in patients with NTM lung disease.
Insmed’s earlier-stage clinical pipeline includes INS1009, a
nebulized prodrug formulation of treprostinil that the company
believes may offer a differentiated product profile with
therapeutic potential in rare pulmonary disorders such as pulmonary
arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF)
sarcoidosis, and severe refractory asthma. To complement its
internal research, Insmed actively seeks in-licensing opportunities
for a broad range of rare diseases. For more information,
visit www.insmed.com.
“Insmed” and “ARIKAYCE” are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
susan.mesco@insmed.com
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024